Clinical Trial Update: Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease [Phase 1, Phase 2]

View source ↗

Summary

The study of ARO-MUC5AC in healthy subjects and patients with muco-obstructive lung disease (asthma and COPD) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• ARO-MUC5AC

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Asthma, Chronic Obstructive Pulmonary Disease | Phase 1, Phase 2 | Status: TERMINATED